McKesson Corporation (MCK)
662.28
-4.08 (-0.61%)
At close: Mar 21, 2025, 2:50 PM
-0.61% (1D)
Bid | 659.88 |
Market Cap | 83B |
Revenue (ttm) | 342.74B |
Net Income (ttm) | 2.81B |
EPS (ttm) | 21.77 |
PE Ratio (ttm) | 30.42 |
Forward PE | 16.43 |
Analyst | Buy |
Ask | 666.58 |
Volume | 410,743 |
Avg. Volume (20D) | 832,797 |
Open | 666.72 |
Previous Close | 666.36 |
Day's Range | 661.50 - 670.79 |
52-Week Range | 464.42 - 670.79 |
Beta | 0.51 |
About MCK
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management,...
Industry Medical - Distribution
Sector Healthcare
IPO Date Nov 10, 1994
Employees 45,000
Stock Exchange NYSE
Ticker Symbol MCK
Website https://www.mckesson.com
Analyst Forecast
According to 13 analyst ratings, the average rating for MCK stock is "Buy." The 12-month stock price forecast is $652, which is a decrease of -1.55% from the latest price.
Stock ForecastsNext Earnings Release
McKesson Corporation is scheduled to release its earnings on May 6, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
-1.18%
McKesson shares are trading lower after the compan...
Unlock content with
Pro Subscription
1 month ago
+0.59%
McKesson shares are trading lower after the company reported Q3 financial results and missed its revenue estimate.